AMERGE Tablets contain naratriptan as the hydrochloride, which is a selective 5-hydroxytryptamine1 receptor subtype agonist.
AMERGE Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
AMERGE Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of AMERGE Tablets have not been established for cluster headache, which is present in an older, predominantly male population.
Media Articles Related to Amerge (Naratriptan)
Six New Studies Illuminate Causes and Comorbidities in Migraine
Source: Medscape NeurologyHeadlines [2016.08.26]
Dr Christoph Diener surveys new data on the causes, treatment, and comorbidities of migraine.
'Tentative' FDA Nod to Trokendi XR for Migraine Prevention
Source: Medscape NeurologyHeadlines [2016.08.22]
The agency granted tentative approval to expand the label for an extended-release topiramate product, already approved for epilepsy, to include prophylaxis of migraine in adults, pending expiry of pediatric exclusivity in 2017.
Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit
Source: Conferences News From Medical News Today [2016.08.16]
As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain.
10th Annual Pain & Migraine Therapeutics Summit, October 19-20, 2016, Chicago
Source: Conferences News From Medical News Today [2016.08.01]
Centrexion Therapeutics has announced a collaborative agreement with BioXcel to develop and commercialize innovative chronic pain therapeutics.
Migraine: Discovery of new genetic risk variants supports a vascular cause
Source: Headache / Migraine News From Medical News Today [2016.06.25]
Researchers have identified 28 new genetic risk variants for migraine, many of which are located in or near genes related to vascular disease.
Published Studies Related to Amerge (Naratriptan)
Published and not fully published double-blind, randomised, controlled trials
with oral naratriptan in the treatment of migraine: a review based on the GSK
Trial Register. 
Naratriptan 2.5Â mg is now an over-the-counter drug in Germany.Naratriptan, when available OTC is a reasonable second or third
choice on the step care ladder in the acute treatment of migraine.
Efficacy of oral naratriptan in the treatment of menstrually related migraine. [2005.10]
The aim of this study was to investigate the efficacy of orally administered 2.5 mg naratriptan in the treatment of menstrually related migraine (MRM). A high percentage of women suffering from migraine report increased frequency of attacks in association with menstruation that may be more severe, of longer duration and more difficult to treat than at other times...
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. [2003.11]
This was a randomized, double-blind study designed to evaluate the comparative efficacy and tolerability of the 40-mg dose of eletriptan and the 2.5-mg dose of naratriptan. Patients (n = 548) meeting International Headache Society (IHS) criteria for migraine were randomized to treat a single migraine attack with either eletriptan 40 mg, naratriptan 2.5 mg, or placebo.
Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. [2003.09]
OBJECTIVE: To evaluate the effect of acute treatment on ictal behavioral functioning of patients with migraine via ambulatory accelerometry. BACKGROUND: The inability to carry out daily activities often complicates migraine attacks. Research into the effects of pharmacological drugs on this outcome parameter in the acute treatment of migraine has been based on subjective reports only... CONCLUSIONS: Consciously perceived clinical and subjective symptoms do not necessarily run in parallel with their behavioral equivalents. It, thus, may be important to assess the effects of treatment on behavioral functioning in the evaluation of the general efficacy of antimigraine drugs in the acute treatment of a migraine attack.
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. [2001.03]
OBJECTIVE: To determine the efficacy of naratriptan 1-mg and 2.5-mg tablets twice daily compared with placebo as short-term prophylaxis of menstrually associated migraine. BACKGROUND: Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open-label study suggest that short-term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine... CONCLUSIONS: Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short-term, prophylactic treatment for menstrually associated migraine.
Clinical Trials Related to Amerge (Naratriptan)
Special Drug Use Investigation for AMERGEŽ Tablet (Long-term) [Completed]
To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on
Japanese patients with migraine headache in clinical setting
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction [Terminated]
The purpose of this study is to determine whether naratriptan, a medication approved for
treatment of migraine, is effective in the treatment of post traumatic headache associated
with cognitive dysfunction.
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet [Completed]
The study is designed to investigate the information on safety and efficacy of naratriptan
tablets on Japanese subjects with migraine headache during Japanese post-marketing
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine. [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan
2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute
treatment of migraine.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan +
naproxen is effective compared each monotherapy for the acute treatment of migraine.
Reports of Suspected Amerge (Naratriptan) Side Effects
Drug Ineffective (4),
Chest Pain (4),
Stress Cardiomyopathy (4),
Troponin T Increased (3),
Eye Pain (3),
Brain Natriuretic Peptide Increased (3),
Vasospasm (3), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Amerge has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Amerge review by 48 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || migraines|
|Dosage & duration:|| || 2.5mg taken 3-4 times per week for the period of 6 yrs|
|Other conditions:|| || high blood pressure|
|Other drugs taken:|| || atenolol, hydrochlorothiazide, lisinopril|
|Benefits:|| || Amerge is effective in reducing the pain and associated symptoms of migraines. |
|Side effects:|| || Mild drowsiness, sometimes mild nausea.|
|Comments:|| || I have very severe migraine disease and have tried many different treatments. None are effective 100% of the time. In my experience, Amerge is the most effective for mild and moderate migraines (Nothing seems to work for severe attacks). I prefer Amerge because the beneficial effects seem to last longer than many of the other anti-migraine meds (often 18-24 hrs.). Also, side effects seem to be negligible(No palpitations and dizziness like with imitrex). The downside is that Amerge takes longer to work (2-4 hrs) than the other triptans. But because of the better safety profile and the longer duration of effectiveness, for me Amerge is a top choice for migraines.|
Page last updated: 2016-08-26